Immunocore Holdings (IMCR) Interest Coverage Ratio (2021 - 2026)
Immunocore Holdings (IMCR) posted Interest Coverage Ratio of 0.11 for Q1 2026, up 101.63% sequentially from 6.45 in Q4 2025, and up 114.62% YoY from 0.05 in Q1 2025.
Powered by 
Analysis
Immunocore Holdings (IMCR) Interest Coverage Ratio (2021 - 2026) Analysis & Trends
Immunocore Holdings has reported Interest Coverage Ratio for 6 years, with the latest figure at 0.11 in Q1 2026.
- Quarterly Interest Coverage Ratio rose 114.62% year-over-year to 0.11 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.5 (up 75.2% YoY) and the FY2025 annual result came in at 0.23, up 70.35% from the prior year.
- Interest Coverage Ratio grew to 0.11 in Q1 2026 per IMCR's latest filing, from 6.45 in the prior quarter.
- Over five years, Interest Coverage Ratio peaked at 3.46 in Q3 2022 and troughed at 15.49 in Q2 2023.
- A 5-year average of 5.23 and a median of 3.05 in 2024 frame the typical range for Interest Coverage Ratio.
- The sharpest annual moves came in 2022 and 2025: Interest Coverage Ratio surged 114.71% in 2022, then tumbled 784.88% in 2025.
- Over 5 years, Interest Coverage Ratio stood at 7.03 in 2022, then plunged by 85.37% to 13.03 in 2023, then soared by 85.26% to 1.92 in 2024, then sank by 235.82% to 6.45 in 2025, then jumped by 101.63% to 0.11 in 2026.
- According to Business Quant data, Interest Coverage Ratio over the past three periods registered 0.11, 6.45, and 2.36 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -493.00 |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -21.24 |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 8.18 |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 2.82 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 1.42 |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.08 |
| 10 | Immunocore Holdings | 1.85 Bn | 965.54 Mn | 114.84 Mn | -0.98 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -0.98 |
| Mar 31, 2026 | 2.39 |
| Dec 31, 2025 | -6.45 |
| Sep 30, 2025 | -2.36 |
| Jun 30, 2025 | -4.89 |
| Mar 31, 2025 | -1.20 |
| Dec 31, 2024 | -2.76 |
| Sep 30, 2024 | -1.98 |
| Jun 30, 2024 | -3.74 |
| Mar 31, 2024 | -8.18 |
| Dec 31, 2023 | -13.03 |
| Sep 30, 2023 | -10.71 |
| Jun 30, 2023 | -10.08 |
| Mar 31, 2023 | -11.76 |
| Dec 31, 2022 | -7.03 |
| Sep 30, 2022 | 3.46 |
| Jun 30, 2022 | -11.78 |
| Dec 31, 2021 | -28.07 |
| Sep 30, 2021 | -23.50 |